[{"AccountsPayableCurrent_0_Q2_USD":3338000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_Q2_USD":4793000.0,"AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1_Q2_USD":1319000.0,"OtherLiabilitiesNoncurrent_0_Q2_USD":2085000.0,"EmployeeRelatedLiabilitiesCurrent_0_Q2_USD":1786000.0,"AllocatedShareBasedCompensationExpense_1_Q2_USD":1319000.0,"AllocatedShareBasedCompensationExpense_2_Q2_USD":3440000.0,"OtherLiabilitiesCurrent_0_Q2_USD":169000.0,"IncreaseDecreaseInOtherOperatingAssets_2_Q2_USD":292000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0_Q2_USD":96910000.0,"NetIncomeLossAvailableToCommonStockholdersBasic_1_Q2_USD":-12115000.0,"NetIncomeLossAvailableToCommonStockholdersBasic_2_Q2_USD":-23438000.0,"ContractWithCustomerLiability_0_Q2_USD":33082000.0,"DepreciationDepletionAndAmortization_2_Q2_USD":615000.0,"DeferredRevenueCurrent_0_Q2_USD":5419000.0,"ComprehensiveIncomeNetOfTax_1_Q2_USD":-12116000.0,"ComprehensiveIncomeNetOfTax_2_Q2_USD":-25623000.0,"ProceedsFromWarrantExercises_2_Q2_USD":1000.0,"OtherAssetsNoncurrent_0_Q2_USD":2271000.0,"NonoperatingIncomeExpense_1_Q2_USD":371000.0,"NonoperatingIncomeExpense_2_Q2_USD":583000.0,"FairValueAdjustmentOfWarrants_1_Q2_USD":0.0,"FairValueAdjustmentOfWarrants_2_Q2_USD":0.0,"AccruedProfessionalFeesCurrent_0_Q2_USD":1470000.0,"PropertyPlantAndEquipmentGross_0_Q2_USD":5233000.0,"IncreaseDecreaseInDeferredRevenue_2_Q2_USD":29013000.0,"InterestAndOtherIncome_1_Q2_USD":371000.0,"ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress_2_Q2_USD":-1844000.0,"ContractWithCustomerLiabilityRevenueRecognized_1_Q2_USD":1251000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_1_Q2_USD":1571000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_2_Q2_USD":2700000.0,"OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_1_Q2_USD":-1000.0,"OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_2_Q2_USD":-2185000.0,"OperatingLeaseWeightedAverageDiscountRatePercent_0_Q2_pure":0.0859,"OperatingLeaseRightOfUseAsset_0_Q2_USD":1627000.0,"OperatingLeaseLiabilityNoncurrent_0_Q2_USD":850000.0,"OperatingLeaseLiabilityCurrent_0_Q2_USD":653000.0,"OperatingLeaseCost_1_Q2_USD":220000.0,"OperatingLeaseCost_2_Q2_USD":443000.0,"NumberOfOperatingSegments_2_Q2_segment":2.0,"ContractWithCustomerLiabilityRevenueRecognized_2_Q2_USD":2002000.0,"NoncurrentAssets_0_Q2_USD":3800000.0,"LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_0_Q2_USD":753000.0,"LesseeOperatingLeaseLiabilityPaymentsDueYearThree_0_Q2_USD":443000.0,"LesseeOperatingLeaseLiabilityPaymentsDue_0_Q2_USD":1503000.0,"LeaseCost_1_Q2_USD":384000.0,"LeaseCost_2_Q2_USD":746000.0,"IncreaseDecreaseInOtherNoncurrentLiabilities_2_Q2_USD":233000.0,"IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_2_Q2_USD":2050000.0,"ForeignCurrencyTransactionGainLossRealized_1_Q2_USD":100000.0,"ForeignCurrencyTransactionGainLossRealized_2_Q2_USD":1400000.0,"EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2_Q2_USD":-3411000.0,"DeferredRevenueNoncurrent_0_Q2_USD":27663000.0,"LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_0_Q2_USD":443000.0,"VariableLeaseCost_2_Q2_USD":303000.0,"InterestAndOtherIncome_2_Q2_USD":583000.0,"AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0_Q2_USD":3060000.0,"Liabilities_0_Q2_USD":47576000.0,"IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_Q2_USD":-267000.0,"IncreaseDecreaseInAccountsReceivable_2_Q2_USD":332000.0,"IncreaseDecreaseInAccountsPayable_2_Q2_USD":1325000.0,"IncomeTaxExpenseBenefit_1_Q2_USD":-97000.0,"IncomeTaxExpenseBenefit_2_Q2_USD":-204000.0,"IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1_Q2_USD":-12212000.0,"IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_Q2_USD":-23642000.0,"GeneralAndAdministrativeExpense_1_Q2_USD":6196000.0,"GeneralAndAdministrativeExpense_2_Q2_USD":11197000.0,"EarningsPerShareBasicAndDiluted_1_Q2_USD":-0.67,"LiabilitiesAndStockholdersEquity_0_Q2_USD":118602000.0,"EarningsPerShareBasicAndDiluted_2_Q2_USD":-1.3,"Depreciation_2_Q2_USD":200000.0,"CommonStockValue_0_Q2_USD":228000.0,"CommonStockSharesOutstanding_0_Q2_shares":18091657.0,"CommonStockSharesIssued_0_Q2_shares":18091657.0,"CashAndCashEquivalentsAtCarryingValue_0_Q2_USD":0.0,"AssetsCurrent_0_Q2_USD":112531000.0,"Assets_0_Q2_USD":118602000.0,"AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_2_Q2_shares":3654012.0,"AdditionalPaidInCapital_0_Q2_USD":198507000.0,"AccumulatedOtherComprehensiveIncomeLossNetOfTax_0_Q2_USD":-3720000.0,"AccountsReceivableNetCurrent_0_Q2_USD":489000.0,"Depreciation_1_Q2_USD":300000.0,"Cash_0_Q2_USD":96910000.0,"LiabilitiesCurrent_0_Q2_USD":16978000.0,"NetCashProvidedByUsedInInvestingActivities_2_Q2_USD":-621000.0,"StockIssuedDuringPeriodValueStockOptionsExercised_1_Q2_USD":9000.0,"ShareBasedCompensation_2_Q2_USD":3440000.0,"ResearchAndDevelopmentExpense_1_Q2_USD":7958000.0,"ResearchAndDevelopmentExpense_2_Q2_USD":15728000.0,"OperatingIncomeLoss_1_Q2_USD":-12583000.0,"OperatingIncomeLoss_2_Q2_USD":-24225000.0,"OperatingExpenses_1_Q2_USD":14154000.0,"OperatingExpenses_2_Q2_USD":26925000.0,"IncomeTaxesPaidNet_2_Q2_USD":38000.0,"CommonStockSharesAuthorized_0_Q2_shares":31995653.0,"CommonStockParOrStatedValuePerShare_0_Q2_GBP":0.01,"NetCashProvidedByUsedInFinancingActivities_2_Q2_USD":12000.0,"CommitmentsAndContingencies_0_Q2_USD":null,"WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1_Q2_shares":18077770.0,"WeightedAverageNumberOfShareOutstandingBasicAndDiluted_2_Q2_shares":18024314.0,"StockholdersEquity_0_Q2_USD":71026000.0,"RetainedEarningsAccumulatedDeficit_0_Q2_USD":-123989000.0,"PropertyPlantAndEquipmentNet_0_Q2_USD":2173000.0,"ProfitLoss_2_Q2_USD":-23438000.0,"PrepaidExpenseAndOtherAssetsCurrent_0_Q2_USD":4318000.0,"PaymentsToAcquirePropertyPlantAndEquipment_2_Q2_USD":621000.0,"NetIncomeLoss_1_Q2_USD":-12115000.0,"NetIncomeLoss_2_Q2_USD":-23438000.0,"NetCashProvidedByUsedInOperatingActivities_2_Q2_USD":8813000.0,"AccruedLiabilitiesCurrent_0_Q2_USD":8221000.0,"VariableLeaseCost_1_Q2_USD":164000.0,"Ticker":"BCYC","CIK":"1761612","name":"BICYCLE THERAPEUTICS PLC","OfficialName":"Bicycle Therapeutics plc American Depositary Shares","form":"10-Q","period":"20200630","fy":"2020.0","fp":"Q2","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"738781455.0","Country":"United Kingdom","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NASDAQ","SP500":"nan","filed":"20200805"}]